Pure Global
NCT06323590

Refining the Role of Mid-induction Bone Marrow Biopsy in Acute Myeloid Leukemia: A Pilot Study

Refining the Role of Mid-induction Bone Marrow Biopsy in Acute Myeloid Leukemia: A Pilot
University of Alabama at Birmingham·ClinicalTrials.govRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Acute Myeloid Leukemia
Study type
Observational
Sponsor & location
Primary sponsor
University of Alabama at Birmingham
Location
Birmingham, United States of America
Timeline & enrollment
Phase
N/A
Start date
May 02, 2024
End date
May 01, 2028
Enrollment
60 participants
Primary outcome

rates of complete remission

Summary

The purpose of the study is to observe the outcomes of patients with acute myeloid leukemia
 who do not receive an immediate second round of chemotherapy after undergoing a standard
 mid-induction bone marrow biopsy.

ICD-10 classifications
Myeloid leukaemiaAcute myeloblastic leukaemia [AML]Myeloid leukaemia, unspecifiedAcute myelomonocytic leukaemiaAcute myeloid leukaemia with 11q23-abnormality
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06323590
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06323590 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Alabama at Birmingham and is currently Recruiting. The study focuses on Acute Myeloid Leukemia. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.